Concurrent onabotulinumtoxina treatment of cervical dystonia and concomitant migraine

Headache

Volumn 52, Issue 8, 2012, Pages 1219-1225

  Winner, Paul K ^a   Sadowsky, Carl H ^a   Martinez, Walter C ^a   Zuniga, Jose A ^a   Poulette, Ashley ^a  

^a Palm Beach Headache Center   (United States)

Author keywords

botulinum toxin; cervical dystonia; chronic migraine; headache; onabotulinumtoxinA; prophylactic treatment

Indexed keywords

AMITRIPTYLINE; ATENOLOL; BOTULINUM TOXIN A; ETIRACETAM; OXCARBAZEPINE; TIZANIDINE; VALPROATE SEMISODIUM;

ACUPUNCTURE; ADULT; ALLODYNIA; ARTICLE; BACKACHE; CERVICAL DYSTONIA; CHIROPRACTIC; CLINICAL ARTICLE; DISEASE DURATION; DISEASE SEVERITY; DRUG SAFETY; DRUG TOLERABILITY; DYSPHAGIA; EXERCISE; EYE DISEASE; FEMALE; FOLLOW UP; HERBAL MEDICINE; HUMAN; MALE; MIGRAINE; MIGRAINE WITH AURA; MIGRAINE WITHOUT AURA; MUSCLE HYPERTONIA; NECK PAIN; OCCUPATIONAL THERAPY; OPEN STUDY; OUTCOME ASSESSMENT; PHYSIOTHERAPY; PILOT STUDY; POSTOPERATIVE PAIN; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOTHERAPY; RATING SCALE; SHOULDER PAIN; SYMPTOM; TREATMENT OUTCOME; WEAKNESS;

EID: 84865861618     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2012.02164.x     Document Type: Article

References (15)

1. Ceballos-Baumann AO,. Evidence-based medicine in botulinum toxin therapy for cervical dystonia. J Neurol. 2001; 248 (Suppl. 1): 14-20.
2. Simpson DM, Blitzer A, Brashear A, et al,. Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008; 70: 1699-1706.
3. Aurora SK, Dodick DW, Turkel CC, et al,. OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010; 30: 793-803.
4. Diener HC, Dodick DW, Aurora SK, et al,. OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010; 30: 804-814.
5. Dodick DW, Turkel CC, DeGryse RE, et al,. OnabotulinumtoxinA for treatment of chronic migraine: Pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 2010; 50: 921-936.
6. Headache Classification Committee of the International Headache Society. The international classification of headache disorders: 2nd edition. Cephalalgia. 2004; 24 (Suppl. 1): 9-160.
7. Olesen J, Bousser MG, Diener HC, et al,. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia. 2006; 26: 742-746.
8. Dowson AJ, Kilminster SG, Salt R,. Clinical profile of botulinum toxin A in patients with chronic headaches and cervical dystonia: A prospective, open-label, longitudinal study conducted in a naturalistic clinical practice setting. Drugs R D. 2008; 9: 147-158.
9. Galvez-Jimenez N, Lampuri CP-PR, Hargreave MJA, Hanson M,. Dystonia and headaches: Clinical features and response to botulinum toxin therapy. In:, Fahn S, DeLong MR, eds. Dystonia 4. V. 94 Ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2004: 321-328.
10. Ondo WG, Gollomp S, Galvez-Jimenez N,. A pilot study of botulinum toxin A for headache in cervical dystonia. Headache. 2005; 45: 1073-1077.
11. Kosinski M, Bayliss MS, Bjorner JB, et al,. A six-item short-form survey for measuring headache impact: The HIT-6. Qual Life Res. 2003; 12: 963-974.
12. Nachit-Ouinekh F, Dartigues JF, Henry P, et al,. Use of the headache impact test (HIT-6) in general practice: Relationship with quality of life and severity. Eur J Neurol. 2005; 12: 189-193.
13. Elkind AH, O'Carroll P, Blumenfeld A, DeGryse R, Dimitrova R,. A series of three sequential, randomized, controlled studies of repeated treatments with botulinum toxin type A for migraine prophylaxis. J Pain. 2006; 7: 688-696.
14. Stewart WF, Lipton RB, Kolodner K,. Migraine disability assessment (MIDAS) score: Relation to headache frequency, pain intensity, and headache symptoms. Headache. 2003; 43: 258-265.
15. BotoxÂ[Prescribing Information]. Irvine, CA: Allergan, Inc; 2011.